MedTrace Logo

Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo

NCT02240693 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2018-11-28

Study results available
· View outcomes & findings →

Summary

The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease

Conditions

  • Alzheimer Disease

Interventions

DRUG

BI 409306

DRUG

Placebo

DRUG

BI 409306

DRUG

Placebo

DRUG

Placebo

DRUG

BI 409306

DRUG

BI 409306

DRUG

Placebo

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-15
Primary Completion
2017-09-18
Completion
2017-10-09

Countries

  • United States
  • Austria
  • Belgium
  • Canada
  • France
  • Germany
  • Italy
  • Netherlands
  • Poland
  • Portugal
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02240693 on ClinicalTrials.gov